

Curriculum Vitae

Personal information

First name / Surname

Alberto Puccini

Address

Via Noto 6, Milan, 20141, Italy

Email and Mobile

alberto.puccini@hunimed.eu; +39-3489350612

Nationality and Date of birth

Italian; Born in Genoa, Italy; 29 Jul 1991, C.F: PCCLRT91L29D969S

Actual Position

Assistant Professor, since Jun 2024; Medical Oncologist, since Jan 2023
Humanitas University; Via Rita Levi Montalcini 4 - 20090 Pieve Emanuele, Milan, Italy
IRCCS Humanitas Research Hospital - Humanitas Cancer Center
Medical Oncology and Hematology Unit - Via Manzoni 56, 20089, Rozzano, Milan, Italy

Education and training

Oct 2024	ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Breast, Gynaecological and GI Cancers, 4-5 October 2024, Zurich, Switzerland
Sept 2023 – Sept 2024	ASCO - Journal of Clinical Oncology's (JCO) Trainee Reviewer Mentoring Program
Sept - Dec, 2023	EORTC Mentoring and Career Development Program 2023 for Early Career Investigators (ECIs)
March 31 st - April 1 st , 2023	ASCO-AIOM Clinical Research Course, Rome, Italy
Dec 2017 – Dec 2022	Medical Oncology Fellow – Mentored by Professor Alberto Sobrero - University of Genoa, Italy U.O. Oncologia Medica 1 - Ospedale Policlinico San Martino - IRCCS, Genoa, Italy Final grade: 50/50 magna cum laude
Nov 2022	Passed the ESMO (European Society for Medical Oncology) Examination held on 10th September 2022 in Paris, France
7-8 Oct 2022	ESMO (European Society for Medical Oncology) Preceptorship on Adolescent and Young Adult Malignancies - Athens, Greece
19-21 Aug 2022	ESMO (European Society for Medical Oncology) Academy – Prague, Czech Republic
Jan – Jul 2021	Junior Project Officer – JPO in Internal Medicine St. Luke Hospital - Woliso – Ethiopia - Doctors with Africa – Cuamm
June 2019	21st EORTC-ESMO-ECCO-AACR Workshop on Methods in Clinical Cancer Research Zeist, Netherlands.
2017 – 2018	Postdoctoral Scholar – Visiting Fellow Professor Heinz-Josef Lenz's Lab. Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California (USC), Los Angeles, CA, USA.
2013 – 2016	Supplementary research training programme – Diploma Supplement University of Genoa, Italy - Focused on Oncology and mentored by Professor Alberto Sobrero
2010-2016	School of Medicine (6 years) - University of Genova, Italy Final grade 110/110 magna cum laude, with merit award
August 2015	Professional Exchange program (IFMSA) as medical student Oncology/Hematology department - Universitätsklinikum Düsseldorf, Germany
August 2014	International Summer School in Internal Medicine University of Copenhagen, Denmark
2002 - 2012	Master degree in Piano Performance Conservatorio 'N. Paganini' in Genoa, Italy. Final grade 9/10
2005 - 2010	High School Diploma - Liceo Scientifico 'Leonardo da Vinci' in Genova. Final grade 100/100

Work experience

2023 – Ongoing	Board of Directors – AIFET (Italian Association of Familial and Hereditary tumors)
2023 – Ongoing	Working Group AIOM (Italian Association of Medical Oncology) Young Oncologists
2021 – 2023	MAC Steering Committee – EORTC European Organisation for Research and Treatment of Cancer
2019	Oncology Professor at International Summer School, University of Copenhagen, Denmark
Sept 2016 – Feb 2017	Medical Doctor collaborator for clinical trials – Ospedale Policlinico San Martino, Genoa, Italy
Since 2015 - ongoing	Medical and scientific Writer - Accademia Nazionale di Medicina, Italy

Scientific publications in peer-reviewed journals

- Airoldi M, ... and **Puccini A***. First-Line Therapy in Metastatic, RAS Wild-Type, Left-Sided Colorectal Cancer: Should Everyone Receive Anti-EGFR Therapy? *Curr Oncol Rep.* 2024 Oct 11. *Corresponding Author
- Tosi F, et al. Curative immune checkpoint inhibitors therapy in patients with mismatch repair-deficient locally advanced rectal cancer: a real-world observational study. *ESMO Open.* 2024 Oct 1;9(10):103929.
- Battistuzzi L, **Puccini A** et al. Routinely Updating Patients With Cancer About Variant of Uncertain Significance Reclassifications: A Premature Responsibility for Community Oncologists. *J Clin Oncol.* 2024 Sep
- Orsi G et al. Germline Pathogenic Variants of Cancer Predisposition Genes in a multicentre Italian cohort of Pancreatic Cancer patients. *Eur J Cancer.* 2024 Jul 16;208:114226
- Gandini A... **Puccini A** and Sobrero AF. Feasibility of stereotactic radiotherapy with pembrolizumab in patients with deficient mismatch repair/microsatellite unstable metastatic colorectal cancer. *ESMO GO June 2024*
- Vanni I, et al. Combining germline, tissue and liquid biopsy analysis by comprehensive genomic profiling to improve the yield of actionable variants in a real-world cancer cohort. *J Transl Med.* 2024
- Stucchi E, ..., **Puccini A***, Santoro A. Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? *Expert Opin Pharmacother.* 2024 Apr 3:1-12 *Corresponding Author
- Germani MM et al. Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset. *ESMO Open April 2024*
- Vasileva-Slaveva M, Morales-Espinosa D, **Puccini A**, et al. Tackling hurdles in front of young clinical investigators in oncology - Results from an international survey. *Eur J Surg Oncol.* 2024 Mar 6;50(6):108031.
- Puccini** et al. ItaLynch: an ongoing Italian study to evaluate the feasibility of mainstreaming the diagnosis of Lynch syndrome in colorectal cancer patients. *ESMO GO, March 2024*

11. Dal Buono A, Puccini A, Franchellucci G et al. Lynch Syndrome: From Multidisciplinary Management to Precision Prevention. *Cancers* 2024, 16, 849.
12. Puccini A, et al. Streamlining the diagnostic pathway for Lynch Syndrome in colorectal cancer patients: a ten-year experience in a single Italian Cancer Center. *Eur J Cancer Prev.* 2024
13. Grillo F et al. BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer. *Histopathology.* 2024 Jan 3.
14. Grillo F et al. Prevalence and type of MMR expression heterogeneity in colorectal adenocarcinoma: therapeutic implications and reporting. *Virchows Arch* 2023 Dec 23.
15. Miliello AM et al. Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline ... (VUS) in BRCA1 and BRCA2 genes. *Cancer Chemother Pharmacol.* 2023
16. Daprà V, ..., Puccini A*, Santoro A. Total Neoadjuvant Treatment for Locally Advanced Rectal Cancer Patients: Where Do We Stand? *Int J Mol Sci.* 2023 Jul 29;24(15):12159 *Corresponding
17. Bartolini M, Seeber A, Puccini A*. Editorial: New therapeutic approaches in microsatellite stable colorectal cancer patients *Front Oncol* 2023 Jul 21; 13:1240963. *Corresponding au
18. Zimmer K et al. PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system. *NPJ Precis Oncol.* 2023 Jul 3;7(1):64
19. Grillo F, et al. Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens. *istochem Cell Biol.* 2023 Jun 7. doi: 10.1007/s00418-023-02202-8. Online ahead of print.
20. Gandini A, ... and Puccini A*, Sciallero S*. The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives. *Front Oncol.* 2023
21. Puccini A, Martelli V, Pastorino A et al. ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care? *Curr Treat Options Oncol.* 2023 Feb;24(2):76-92
22. Cremante M, Pastorino A, Pozzano M, et al. Reliability of patient reported toxicities during adjuvant chemotherapy. *Eur J Cancer.* 2023 Jan 14; 182:115-121
23. Puccini A, Seeber A, Berger MD. Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective. *Cancers (Basel).* 2022 Oct 3;14(19):4828
24. Puccini A, et al. Clinical Significance of Germline Pathogenic Variants among 51 Cancer Predisposition Genes in an Unselected Cohort of Italian Pancreatic Cancer Patients. *Cancers* 2022
25. Kocher F, Puccini A, et al. Multi-omic characterization of pancreatic ductal adenocarcinoma relates CXCR4 mRNA expression levels to potential clinical targets. *Clin Cancer Res* 2022
26. Puccini A, et al. Molecular profiling of signet-ring-cell carcinoma (SRCC) from the stomach and colon reveals potential new therapeutic targets. *Oncogene.* 2022 Jun;41(26):3455-3460.
27. Boccaccino A et al. Encorafenib plus cetuximab with or without binimetinib in BRAF V600E mutated metastatic colorectal cancer patients: real-life data from an Italian multicenter experience. *ESMO Open.* 2022
28. Dalmasso B*, Puccini A* et al. Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. *Int. J. Mol. Sci.* 2022, 23, 4709. *Co-first
29. Catalano F, ... and Puccini A*. Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer. *Cancers* 2022, 14, 1388. *Corresponding A,
30. Salem ME, et al. Landscape of KRASG12C, associated genomic alterations, and interrelation with immuno-oncology biomarkers in KRAS-mutated cancers. *JCO Precis Oncol.* 2022 Mar;6:e2100245
31. Seeber A, et al. Comprehensive analysis of R-spondin fusions and RNF43 mutations implicate novel therapeutic options in colorectal cancer. *Clin Cancer Res.* 2022 Mar 7
32. Puccini A, et al. Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. *NPJ Precis Oncol* 2021 Oct 27;5(1):95.
33. Zimmer K, Kocher F, Puccini A et al. Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. *Front Oncol.* 2021 Oct
34. Salem ME, Puccini A, Xiu J, et al. Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early-Onset Colorectal Cancer. *Oncologist.* 2021
35. Naseem M, et al. Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. *Sci Rep* 2021
36. Battistuzzi L, Puccini A, Sciallero S. Kn177: from precision medicine to precision prevention; *N Engl J Med* 2021; 384:971-973
37. Seeber A, Zimmer K, Kocher F, Puccini A, et al. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. *ESMO Open.* 2020
38. Puccini A, et al. Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). *Clin Cancer Res* 2020 Nov 15;26(22):5943-5951
39. Tokunaga R, Xiu J, Goldberg RM et al. The impact of ARID1A mutation on molecular characteristics in colorectal cancer. *Eur J Cancer.* 2020 Oct; 140:119-129
40. Sobrero A, Puccini A, Shi Q, et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. *Eur J Cancer.* 2020 Sep 3;138:182-188.
41. Puccini A*, Battaglin F*, Iaia ML, et al. Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies. *J Immunother Cancer* 2020;8:e000404.
42. Zimmer K, Puccini A, Xiu J, et al. WRN-mutated colorectal cancer is characterized by a distinct genetic phenotype. *Cancers (Basel).* 2020 May 22;12(5):E1319.
43. Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. *ESMO Open.* 2020 Jun;5(3):e000682
44. Salem ME*, Bodor JN*, et al. Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability-high solid tumors. *Int J Cancer* 2020.
45. Berger MD, et al. A Polymorphism Within the R-spondin 2 Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated With FOLFIRI/bevacizumab: Data From FIRE-3 and TRIBE Trials. *Eur J Cancer* 2020
46. Grassi M, Spagnoletti A, Puccini A*. Metastatic sarcoma: tailored strategies for a heterogeneous disease. *Memo - Magazine of European Medical Oncology* April 2020; *Corresponding author
47. Salem ME, Puccini A, Tie J. Redefining Colorectal Cancer by Tumor Biology. *Am Soc Clin Oncol Educ Book.* Mar 2020; 40: 1-13
48. Salem ME, Battaglin F, ..., Puccini A, et al. Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. *The Oncologist* 2020
49. Puccini A, Bregni G, Sciallero S. Maintenance Olaparib for Metastatic Pancreatic Cancer. *N Engl J Med.* 2019 Oct 10;381(15):1491-1492.
50. Battaglin F*, Puccini A*, et al. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. *Cancer Management and Research* 2019. *Co-first authors
51. Puccini A, et al. Impact of polymorphisms within genes involved in regulating DNA methylation in metastatic colorectal cancer patients enrolled in three independent, randomized, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC, and FIRE-3. *Eur J Cancer* 2019; 111: 138-147
52. Tokunaga R, et al. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: a meta-analysis using TRIBE, MAVERICC, and FIRE3. *Int J Cancer.* 2019
53. Puccini A*, Marin-Ramos* NI, Bergamo F, et al. Safety and Tolerability of c-MET Inhibitors in Cancer. *Drug Saf.* 2019; 42(2): 211-233. *Co-first authors
54. Tokunaga R, et al. Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer. *Clin Cancer Res* 2019 15;25(10):3096-3103.
55. Tokunaga R, Naseem M, Lo JH, et al. B cell and B cell-related pathways for novel cancer treatments. *Cancer Treat Rev.* 2019; 73:10-19
56. Puccini A, Battaglin F, Lenz HJ. Management of Advanced Small Bowel Cancer. *Curr Treat Options Oncol.* 2018 Nov 5;19(12):69.
57. Tokunaga R, et al. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. *Clin Colorectal Cancer* 2019
58. Puccini A, Marshall JL, and Salem ME. Molecular Variances Between Right- and Left-sided Colon Cancers. *Curr Colorectal Cancer Rep* 2018; 14 (5): 152-158.
59. Sonbol MB, Bekaii-Saab TS, Puccini A, and Salem ME. Young Patients with Colorectal Cancer: Risk, Screening, and Treatment. *Curr Colorectal Cancer Rep* 2018; 14 (5): 159-165.
60. Puccini A, Lenz HJ, Marshall JL, et al. Impact of Patient Age on Molecular Alterations of The Left-Sided Colorectal Tumors. *The Oncologist* 2019; 24:319-326.
61. Battaglin F, Naseem M, Puccini A, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. *Cancer Cell Int.* 2018; 18:99.
62. McSkane M, et al. Association between height and clinical outcome in metastatic colorectal cancer patients enrolled in a randomized, phase III clinical trial: data from the FIRE-3 study. *Clin Colorectal Cancer.* 2018
63. Salem ME, Puccini A, et al. Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. *Oncologist.* 2018
64. Salem ME*, Puccini A*, et al. Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. *Mol Cancer Res.* 2018. *Co-first authors
65. Battaglin F, Puccini A, Naseem M, et al. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. *J Cancer Metastasis Treat* 2018; 4:12.
66. Naseem M, Barzi A, Brezden-Masley C, Puccini A, et al. Outlooks on Epstein-Barr virus associated gastric cancer. *Cancer Treat Rev.* 2018; 66:15-22.
67. Battaglin F*, Puccini A*, Intini R, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. *Expert Rev Anticancer Ther.* 2018; 19:1-16 *Co-first authors
68. Puccini A, Lenz H-J. Practice-changing updates in the adjuvant and metastatic setting. *Nat Rev Clin Oncol.* 2018;15(2):77-78.
69. Berger MD, et al. A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab. *Clin Cancer Res.* 2018
70. Tokunaga R, Zhang W, Naseem M, Puccini A, et al. CXCL10, CXCL11/CXCR3 axis for immune activation-A target for novel cancer therapy. *Cancer Treat Rev* 2018;63:40
71. Puccini A, Berger MD, Naseem M, et al. Colorectal cancer: epigenetic alterations and their clinical implications. *Biochim Biophys Acta* 2017; 1868(2): 439-448.
72. Sobrero A, Puccini A, Bregni G, Bruzzi P. The urgent need to improve the tools to assess clinical benefit and value of cancer treatment. *Eur J Cancer* 2017; 83: 324-328.
73. Puccini A, Lenz HJ. New perspectives for colorectal cancer. *Oncotarget* 2017; 8: 41782-41783.
74. Puccini A, Berger MD, Zhang W, Lenz HJ. What We Know About Stage II and III Colon Cancer: It's Still Not Enough. *Target Oncol* 2017; 12(3): 265-275.
75. Pastorino A, Bregni G, Damiani A, et al. Cisplatin-related atrial fibrillation during PEB chemotherapy for testicular seminoma: a case report. *J Health Med Inform* 2016; 7:3

H-Index Scholar: 27; H-Index Scopus 24

Merit Awards

- ESMO Gastrointestinal Cancers 2024, ESMO Merit Award and Travel Grant.
- ASCO Annual Meeting, Chicago, June 2021, Conquer Cancer Foundation of ASCO – Robert G. Cox Memorial Endowed Merit Award in Molecularly Targeted Developmental Therapeutics
- Carlo Erba Foundation – C. Cioffrese Award 2020 on Oncology for young investigators and researchers
- Federico Calabresi Foundation Award 2020: best publication in a high impact factor journal among young oncologists (under 40)
- AIOM (Italian Association of Medical Oncology) Liguria Sept 2019, Young Oncologists Award “Giovanni Gardin”
- ESMO 2019 Congress, Barcelona, Sept-Oct 2019, ESMO Merit Award and travel grant
- ASCO Annual Meeting, Chicago, June 2019, Conquer Cancer Foundation of ASCO/Loxo Oncology Endowed Merit Award
- ASCO Gastrointestinal Cancers Symposium, Jan 2019, Conquer Cancer Foundation Merit Award.
- ESMO 2018 Congress, Munich, October 2018, ESMO Merit Award and travel grant
- ASCO Annual Meeting, Chicago, June 2018, Conquer Cancer Foundation of ASCO/Drs. Rachna and Puneet Shroff Endowed Merit Award

I am aware of the penal sanctions foreseen in case of false declarations as established by art. 76 of law 445/2000.

I hereby grant permission to use my personal data in accordance with GDPR 2016/679.

As Nov 2024,

Alberto Puccini

